Business Description
Revvity Inc
NAICS : 334516
SIC : 8071
ISIN : US7140461093
Total Employee Number:
11,000Compare
Compare
Traded in other countries / regions
RVTY.USAPKI.Mexico0KHE.UKPKN.GermanyR1VT34.Brazil Index Membership
S&P 500Russell 1000Russell 3000 IPO Date
1972-06-01Description
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.31 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.46 | |||||
Debt-to-EBITDA | 4.52 | |||||
Interest Coverage | 5.44 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.96 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.2 | |||||
3-Year EBITDA Growth Rate | -11.1 | |||||
3-Year EPS without NRI Growth Rate | -9.9 | |||||
3-Year FCF Growth Rate | -2.4 | |||||
3-Year Book Growth Rate | 3.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.87 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.07 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 67.39 | |||||
9-Day RSI | 68.63 | |||||
14-Day RSI | 67.49 | |||||
3-1 Month Momentum % | 8.78 | |||||
6-1 Month Momentum % | 13.1 | |||||
12-1 Month Momentum % | 29.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.8 | |||||
Quick Ratio | 1.5 | |||||
Cash Ratio | 0.8 | |||||
Days Inventory | 106.57 | |||||
Days Sales Outstanding | 87.41 | |||||
Days Payable | 48.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.22 | |||||
Dividend Payout Ratio | 0.05 | |||||
Forward Dividend Yield % | 0.22 | |||||
5-Year Yield-on-Cost % | 0.22 | |||||
3-Year Average Share Buyback Ratio | 3.8 | |||||
Shareholder Yield % | 3.29 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.98 | |||||
Operating Margin % | 12.27 | |||||
Net Margin % | 8.16 | |||||
EBITDA Margin % | 25.37 | |||||
FCF Margin % | 19.17 | |||||
OCF Margin % | 21.55 | |||||
ROE % | 3.25 | |||||
ROA % | 1.96 | |||||
ROIC % | 3.08 | |||||
3-Year ROIIC % | 11.35 | |||||
ROC (Joel Greenblatt) % | 26.53 | |||||
ROCE % | 2.97 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 62.01 | |||||
Forward PE Ratio | 22.11 | |||||
PE Ratio without NRI | 24.34 | |||||
Shiller PE Ratio | 28.6 | |||||
Price-to-Owner-Earnings | 29.35 | |||||
PS Ratio | 5.05 | |||||
PB Ratio | 2.01 | |||||
Price-to-Free-Cash-Flow | 26.35 | |||||
Price-to-Operating-Cash-Flow | 23.43 | |||||
EV-to-EBIT | 51.6 | |||||
EV-to-Forward-EBIT | 25.69 | |||||
EV-to-EBITDA | 22.81 | |||||
EV-to-Forward-EBITDA | 18.52 | |||||
EV-to-Revenue | 5.79 | |||||
EV-to-Forward-Revenue | 5.63 | |||||
EV-to-FCF | 30.19 | |||||
Price-to-GF-Value | 1.11 | |||||
Price-to-Projected-FCF | 1.22 | |||||
Price-to-Median-PS-Value | 1.22 | |||||
Earnings Yield (Greenblatt) % | 1.94 | |||||
FCF Yield % | 3.84 | |||||
Forward Rate of Return (Yacktman) % | -12.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:RVTY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Revvity Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,911.811 | ||
| EPS (TTM) ($) | 2.1 | ||
| Beta | 1.208 | ||
| 3-Year Sharpe Ratio | 0.14 | ||
| 3-Year Sortino Ratio | 0.22 | ||
| Volatility % | 35.29 | ||
| 14-Day RSI | 67.49 | ||
| 14-Day ATR ($) | 3.805578 | ||
| 20-Day SMA ($) | 123.0985 | ||
| 12-1 Month Momentum % | 29.98 | ||
| 52-Week Range ($) | 81.22 - 133 | ||
| Shares Outstanding (Mil) | 111.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Revvity Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Revvity Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-24 | In 171 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-02 08:00 | In 150 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-02 | In 149 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-27 08:00 | In 52 days | ||
| Third quarter earnings results for 2026 | 2026-10-27 | In 51 days | ||
| USD 0.070000 Cash Dividend | 2026-10-23 | In 47 days | ||
| Guidance call for 2026 | 2026-09-15 09:05 | In 10 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-14 08:30 | In 9 days | ||
| Wells Fargo 21st Annual Healthcare Conference | 2026-09-09 08:45 | In 4 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 07:30 | 115.22 (+2.44%) |
Show
Entries
Revvity Inc Frequently Asked Questions
What is Revvity Inc(RVTY)'s stock price today?
The current price of RVTY is $130.22. The 52 week high of RVTY is $133.00 and 52 week low is $81.22.
When is next earnings date of Revvity Inc(RVTY)?
The next earnings date of Revvity Inc(RVTY) is 2026-10-27 Est..
Does Revvity Inc(RVTY) pay dividends? If so, how much?
The Dividend Yield %  of Revvity Inc(RVTY) is 0.22% (As of Today), Highest Dividend Payout Ratio of Revvity Inc(RVTY) was 0.19. The lowest was 0.03. And the median was 0.06. The  Forward Dividend Yield % of Revvity Inc(RVTY) is 0.22%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NYSE:RVTY
EdgePoint Global
Bullish
2025 Q1
EDGEPOINT CANADIAN PORTFOLIO
· 65 holdings
What the manager wrote
Revvity Inc. is a global life sciences company that has shifted its innovation focus to faster growing areas such as cell and gene therapy, proteins, genomics, and biologics. This strategic pivot positions Revvity to capitalize on emerging trends in the life sciences sector, enhancing its growth potential. As a recent spinoff of PerkinElmer Inc., Revvity is well-placed to leverage its legacy while expanding its research solutions to a broad client base, making it a compelling investment opportunity.
Press Release
Articles on Revvity Inc
EdgePoint Investment Group Inc. Trims Twist Bioscience Corp (TWST) Stake -- Shares Trade 160% Above GF Value
Aug 21, 2026
EdgePoint Investment Group Trims Restaurant Brands International (QSR) Stake in Q2 2026
Aug 21, 2026
Headlines
See More- 1
Aug 30, 2026
Notable healthcare headlines for the week: Veeva Systems, Boston Scientific in focus
Seeking Alpha • 8:05am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers